Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30529022 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTCYP19A1TGFBR1 | |
| SCHEMBL2739657 | 0.83 | LMNA (0.40) | L3MBTL1ALDH1A1MAPTKDM4CCNR2 | |
| SCHEMBL24387317 | 0.79 | NR4A2 (0.36) | L3MBTL1ALDH1A1MAPTKDM4CCNR2 | |
| SCHEMBL31543170 | 0.79 | LOXL2 (0.36) | L3MBTL1ALDH1A1MAPTKDM4CCNR2 | |
| SCHEMBL16369760 | 0.79 | LOXL2 (0.36) | L3MBTL1ALDH1A1MAPTKDM4CCNR2 | |
| SCHEMBL12782189 | 0.79 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1MAPTCYP19A1KDM4C | |
| SCHEMBL9444981 | 0.77 | SYK (0.38) | L3MBTL1TGFBR1SMN1; SMN2 | |
| SCHEMBL29608524 | 0.77 | UHRF1 (0.48) | L3MBTL1ALDH1A1MAPTTGFBR1MEN1 | |
| SCHEMBL129055 | 0.77 | UHRF1 (0.48) | L3MBTL1ALDH1A1MAPTTGFBR1MEN1 | |
| SCHEMBL22624035 | 0.76 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1MAPTKDM4CCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3681883-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094278-A | Diphenyl derivatives and their use | 诺华股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019053090-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| CN-102015636-B | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2014-08-13 | — | — | CN | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| CN-102015636-A | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2011-04-13 | — | — | CN | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| EP-1188755-B1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6723722-B1 | BLOOD COAGULATION FACTOR X INHIBITORS; ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1188755-A1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | L3MBTL1 1366/4885ALDH1A1 921/4885MAPT 2084/4885 |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | L3MBTL1 4229/4885ALDH1A1 2066/4885MAPT 3900/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | L3MBTL1 1366/4885ALDH1A1 921/4885MAPT 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.